As a deadly disease lacking an FDA-approved targeted therapy, triple-negative breast cancer (TNBC) involves a complicated and entangled network of oncogenic processes in which long non-coding RNAs (lncRNAs), a novel class of regulatory RNA molecules, may play important roles. The proposed study will genetically exploit lncRNA-regulated cellular networks in TNBC to identify an improved therapeutic strategy. Our research has illuminated lncRNA involvement in TNBC metastasis and metabolic reprogramming. One lncRNA, LINK-A, is upregulated in TNBC and is negatively correlated with breast cancer patient outcomes. Tissue-specific expression of LINK-A in mouse mammary glands drives tumor development and lung metastasis, which shares morphological and transcriptional similarity to human TNBC. Furthermore, the expression of LINK- A facilities an immunosuppressive environment and profoundly impacts CD9+ T-cell infiltration via lncRNA- mediated antigenicity loss. Mechanistically, LINK-A concurrently activates multiple oncogenic signaling pathways and promotes TRIM71-dependent degradation of the peptide-loading complex, leading to impaired antigen presentation. Therefore, LINK-A transgenic mice should serve as a powerful tool for dissecting the molecular complexity of TNBC and assessing precise therapeutic formulations against TNBC. Since most pathway inhibitors in TNBC clinical trials have been unsuccessful, a lncRNA-directed therapeutic approach, with the appropriate combination of immunotherapy, may optimize the efficacy of therapies for TNBC. The long-term goal of the proposal is to demonstrate the molecular mechanisms of lncRNA-mediated antigenicity loss and immunosuppression so that improved strategies can be developed to reduce TNBC morbidity and mortality. Our central hypothesis is that LINK-A promotes the initiation and immunoresistance of breast cancer, which can be attenuated in vivo by a combinatorial treatment approach. We will address our hypothesis from following aspects: we will first define the underlying molecular mechanism of lncRNA-dependent antigenicity loss. We will then restore antigenicity by targeting lncRNA and lncRNA-related signaling events. Finally, we will ascertain the functional importance of lncRNAs in breast cancer tumorigenesis. Emerging evidence of the oncogenic involvement of lncRNAs, as well as their implicated roles in mediating immunosurveillance and immunosuppression, warrants further characterization of TNBC-specific lncRNAs and future applications that hinge on their activity. Our goal is to demonstrate that LINK-A, as a hallmark of TNBC, may serve as a diagnostic marker that predicts a cancer?s sensitivity to immunotherapy. Thus, a strategy that combines immune checkpoint blockers and lncRNA-based therapeutic strategies has the potential to significantly advance TNBC treatment. In the long run, these research findings will benefit the cancer community by introducing the robust clinical effects of targeting lncRNAs and a well-defined means of stratifying patients based on these oncogenic lncRNAs.

Public Health Relevance

Triple-negative breast cancer (TNBC) remains as the only subtype of breast cancer without a targeted therapy with less than 20% response rate upon anti-PD1/PD-L1 blockage, demanding characterization of biomarkers and molecular mechanisms of immunoresistance, by which long non-coding RNAs (lncRNA) show promise. Our preliminary data indicated the correlation of lncRNAs and the resistance of TNBC patients upon anti-PD-1 antibody treatment and demonstrated the lncRNA-dependent antigenicity loss during mammary gland tumor initiation and progression with genetic evidence. The proposed study will dissect the underlying molecular mechanism of lncRNA-dependence antigenicity loss and determine that targeting lncRNAs restores antigenicity to prevent the tumor initiation and further sensitizing TNBC tumors upon immunotherapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA231011-03
Application #
10092976
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Mietz, Judy
Project Start
2019-03-01
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
3
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Microbiology/Immun/Virology
Type
Hospitals
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030